Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Blood and filters: The intersection of myelodysplastic syndrome and renal failure in u.S. mortality trends (1999–2023)

Haseeb Tareen, Atif Malik, Ali Zubair et al. Nov 03, 2025 pp. 7395-7395 10.1182/blood-2025-7395

Abstract Introduction: Myelodysplastic syndromes (MDS) are clonal bone marrow disorders with a major worldwide and U.S....

Novel composite end-points toxicity/progression-free survival (tfPFS) and toxicity-free complete remission (tfCR100) after CAR-T cell therapy for diffuse large B cell lymphoma: Cell therapy consortium analysis.

Veronika Bachanova, Qing Cao, Marie Hu et al. Nov 03, 2025 pp. 400-400 10.1182/blood-2025-400

Abstract The success of CAR T is typically assessed by disease response and rates of immune complications like Cytokine Release Syndrome (CR...

Allogeneic induced pluripotent stem cell-derived invariant natural killer T cell therapy: A phase 1 clinical Trial

Takahiro Aoki, Tomohisa Iinuma, Tomoya Kurokawa et al. Nov 03, 2025 pp. 5927-5927 10.1182/blood-2025-5927

Abstract Introduction: The invariant Natural Killer T (iNKT) cell is a T cell subset characterized by the expression of...

Results of abatacept addition to post transplant cyclophosphamide-based GVHD prophylaxys in allogeneic hematopoyetic stem cell transplantation

Paula Fernández-Caldas, María del Pilar Montero Anton, Rebeca Bailen et al. Nov 03, 2025 pp. 7778-7778 10.1182/blood-2025-7778

Abstract Background: Graft-versus-host disease (GVHD) remains a leading cause of morbidity and mortality following allogeneic hematopoietic...

Cardiovascular disease risk scores as predictors of cardiovascular disease and heart failure in allogeneic hematopoietic cell transplant survivors

Victoria Stepanyants, Xuefei Jia, William Liu et al. Nov 03, 2025 pp. 2488-2488 10.1182/blood-2025-2488

Abstract Survivors of allogeneic hematopoietic cell transplant (allo-HCT) have a significantly higher risk of developing atherosclerotic car...

Implementation challenges of the learner clinical trial in pregnant women with sickle cell disease in Angola

Catarina Ginete, Miguel Brito, Tatiana Gomes et al. Nov 03, 2025 pp. 6149-6149 10.1182/blood-2025-6149

Abstract Sickle Cell Disease (SCD), a severe inherited blood disorder, poses significant risks during pregnancy, particularly in regions lik...

Romiplostim N01 enhances platelet engraftment in ASCT using non-cryopreserved pbscs for plasma cell neoplasms: A single-center phase II study in China

Xianfu Sheng, Huijin Hu, Yuechao Zhao et al. Nov 03, 2025 pp. 5972-5972 10.1182/blood-2025-5972

Abstract Autologous hematopoietic stem cell transplantation (ASCT) remains a standard of care for plasma cell neoplasms, including multiple...

Dynamic mutational evolution and transcriptomic remodeling on 3rd-generation TKI therapy in TKI-resistant patients with chronic myeloid leukemia

Xiaoshuai Zhang, Lu Yu, Zongru Li et al. Nov 03, 2025 pp. 5540-5540 10.1182/blood-2025-5540

Abstract BackgroundThird-generation tyrosine kinase inhibitors (3G-TKIs), olverembatinib and ponatinib, improved outcomes for patients with...

SETD2 deficiency in chronic myeloid leukemia (CML) contributes to tyrosine kinase inhibitor (TKI) resistance and disease acceleration by enhancing genetic instability and rewiring cellular metabolism and might be a novel biomarker of high risk disease since diagnosis

Manuela Mancini, Lucia Romagnoli, Sara De Santis et al. Nov 03, 2025 pp. 5557-5557 10.1182/blood-2025-5557

Abstract There is an active quest for biomarkers of high-risk disease in CML. ASXL1 and other cancer gene mutations, some additional cytogen...

Comparative long-term cardiovascular and hematologic outcomes of gemtuzumab ozogamicin containing regimens versus idarubicin containing regimens in acute promyelocytic leukemia: A propensity-matched analysis of real-world multicenter data

Hareem Saleem, Aakriti Adhikari, abdulwali khan et al. Nov 03, 2025 pp. 6964-6964 10.1182/blood-2025-6964

Abstract Background All-trans retinoic acid (ATRA)-based regimens have revolutionized the treatment of acute promyelocyt...

Preliminary pharmacokinetic and MRD results from AML patients treated with 7- and 14-day dosing schedule of emavusertib added to combination therapy with azacitidine and venetoclax

Cristina Papayannidis, Ulf Schnetzke, Maximilian Fleischmann et al. Nov 03, 2025 pp. 5201-5201 10.1182/blood-2025-5201

Abstract Background Emavusertib, an oral IRAK4 and FLT3 inhibitor, is being tested in a Phase 1, single-arm, open-label,...

Platelet dysfunction in Ehlers–Danlos syndrome is associated with low GPVI and PAR1 expression on platelets

Mariia Kumskova, Gagan Flora, Manasa Nayak et al. Nov 03, 2025 pp. 4801-4801 10.1182/blood-2025-4801

Abstract Introduction: People with Ehlers–Danlos syndrome (EDS) are at an increased risk for hemorrhagic events, which can range from minor...

All-trans retinoic acid mitigates IL-1β-driven NEU1-mediated megakaryocyte desialylation and dysfunction in immune thrombocytopenia

Peng Zhao, Jing-Li Han, Hai-Xia Fu et al. Nov 03, 2025 pp. 1243-1243 10.1182/blood-2025-1243

Abstract Introduction Immune thrombocytopenia (ITP) is marked by autoimmune platelet destruction and impaired thrombopoiesis, with neuramini...

Mendelian randomization reveals the causative role of genetically predicted viral infection in pan-lymphoma risk

Wanying Chen, Jin Zhou, Qian Wang et al. Nov 03, 2025 pp. 5449-5449 10.1182/blood-2025-5449

Abstract Background: While observational studies have suggested associations between viral infections and lymphoma risk, causal relationship...

Refined design of a CD117 antibody-drug conjugate safely and effectively conditions non-human primates for autologous transplant-based gene therapy

Lev Gorfinkel, Boya Liu, Yi Liu et al. Nov 03, 2025 pp. 5871-5871 10.1182/blood-2025-5871

Abstract Introduction: Standard chemotherapy and irradiation-based conditioning for hematopoietic stem cell transplant (HCT) and autologous-...

Prospective hydroxyurea impact on cerebral magnetic resonance imaging from a 30-month trial of children with sickle cell anemia in Uganda

Richard Idro, Bill Wambaka, Vincent Mboizi et al. Nov 03, 2025 pp. 617-617 10.1182/blood-2025-617

Abstract Introduction: Children with sickle cell anemia (SCA) often develop cerebral vasculopathy early in life. Vascular injury is manifest...

Analysis of safety and efficacy of carmen, GMALL, LMB, and other intensive chemotherapy combinations in an international series of HIV-positive patients with burkitt lymphoma: A study of the HIV lymphoma network of the european hematology association

Andrés José María Ferreri, Federico Erbella, Philipp Schommers et al. Nov 03, 2025 pp. 478-478 10.1182/blood-2025-478

Abstract Introduction: Current treatment strategy for HIV-associated Burkitt lymphoma (BL) typically rely on intensive chemotherapy regimens...

Treatment-requiring paroxysmal nocturnal hemoglobinuria in association with myeloproliferative neoplasms (MPNs): Clinical correlations and outcomes

Priyansh Faldu, Rania Abdelaziz, Muhammad Yousuf et al. Nov 03, 2025 pp. 3188-3188 10.1182/blood-2025-3188

Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder caused by PIGA mutations, resulti...

Validation of the FL/IL6 score, a new dynamic cytokine-based risk-model in adults with acute myeloid leukemia, a prospective multicentre filo study.

Pierre Peterlin, Joëlle Gaschet, Sarah Bertoli et al. Nov 03, 2025 pp. 5247-5247 10.1182/blood-2025-5247

Abstract Background: In a recent monocentric study in adults with acute myeloid leukemia (AML), it was shown that combining the kinetic prof...

Autologous CD19-directed CAR-T exhibit promising safety and efficacy in refractory primary immune thrombocytopenia

Mengli Xu, Shiqi Li, Zhi Yang et al. Nov 03, 2025 pp. 4175-4175 10.1182/blood-2025-4175

Abstract Background: Refractory primary immune thrombocytopenia (ITP) patients are characterized by great treatment diff...

Glofitamab plus gemcitabine and oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Efficacy and safety in patient subgroups

Haifaa Abdulhaq, William Townsend, Matthew Ku et al. Nov 03, 2025 pp. 3743-3743 10.1182/blood-2025-3743

Abstract Background Glofitamab, a CD20xCD3 bispecific antibody, plus GemOx (Glofit-GemOx) has shown overall survival (OS), progression-free s...

Differential prognostic impact of chromatin modifier mutations in peripheral T-cell lymphoma: KMT2A emerges as a critical biomarker

Youngwoo Jeon, Tong-Yoon Kim, Tae-Jung Kim et al. Nov 03, 2025 pp. 5325-5325 10.1182/blood-2025-5325

Abstract Background: Peripheral T-cell lymphomas (PTCLs) remain one of the most challenging lymphoma subtypes to treat, with consistently po...

LOX1 expression identifies a population of polymorphonuclear myeloid-derived suppressor cells that are highly enriched in bone marrow samples of treatment-Naïve and BTKi-Relapsed/Refractory WM patients and show constitutive activation of BTK

Maria Luisa Guerrera, Abigail Peachey, Xia Liu et al. Nov 03, 2025 pp. 5731-5731 10.1182/blood-2025-5731

Abstract Introduction: Immune microenvironment dysregulation is a hallmark of early/smoldering Waldenstrom's Macroglobulinemia (WM) that und...

Unfavorable outcomes in pediatric PAX5r B-cell precursor acute lymphoblastic leukemia: FLT3 targeting as a potential novel treatment strategy

Nicolò Peccatori, Alessia Curto, Daniela Silvestri et al. Nov 03, 2025 pp. 760-760 10.1182/blood-2025-760

Abstract Background: PAX5-altered acute lymphoblastic leukemia (PAX5alt ALL) is a recently defined molecular subtype of BCP-ALL, which displ...

Targeting ephrin A3 in the bone marrow niche offers a promising therapeutic strategy to impede hematopoietic stem cell maintenance in MDS patients

Syed Mian, Marie Goulard, Fatihah Mohamad Nor et al. Nov 03, 2025 pp. 859-859 10.1182/blood-2025-859

Abstract Myelodysplastic syndrome (MDS) comprises a group of clonal stem cell disorders characterized by ineffective haematopoiesis. Using h...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page